Literature DB >> 30266609

Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients.

Tuy Nga Brignol1, Patrice E Fort2, Dora Fix Ventura3, Ramin Tadayoni4, Alvaro Rendon5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30266609      PMCID： PMC6394826          DOI： 10.1016/j.jaapos.2018.07.347

Source DB:  PubMed          Journal:  J AAPOS        ISSN： 1091-8531            Impact factor:   1.220


× No keyword cloud information.
  5 in total

1.  Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients.

Authors:  Melissa L Rice; Brenda Wong; Paul S Horn; Michael B Yang
Journal:  J AAPOS       Date:  2018-05-04       Impact factor: 1.220

2.  Electrical myotonia and cataract in X-linked muscular dystrophy (mdx) mouse.

Authors:  T Kurihara; M Kishi; N Saito; M Komoto; T Hidaka; M Kinoshita
Journal:  J Neurol Sci       Date:  1990-10       Impact factor: 3.181

3.  Duchenne/Becker muscular dystrophy: correlation of phenotype by electroretinography with sites of dystrophin mutations.

Authors:  D A Pillers; K M Fitzgerald; N M Duncan; S M Rash; R A White; S J Dwinnell; B R Powell; R E Schnur; P N Ray; G W Cibis; R G Weleber
Journal:  Hum Genet       Date:  1999 Jul-Aug       Impact factor: 4.132

4.  Red-green color vision impairment in Duchenne muscular dystrophy.

Authors:  Marcelo Fernandes Costa; Andre Gustavo Fernandes Oliveira; Claudia Feitosa-Santana; Mayana Zatz; Dora Fix Ventura
Journal:  Am J Hum Genet       Date:  2007-04-13       Impact factor: 11.025

5.  Lack of dystrophin protein Dp71 results in progressive cataract formation due to loss of fiber cell organization.

Authors:  Patrice E Fort; Marie Darche; José-Alain Sahel; Alvaro Rendon; Ramin Tadayoni
Journal:  Mol Vis       Date:  2014-11-04       Impact factor: 2.367
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.